Latest News
People who have had post-operative radiotherapy for prostate cancer may not also need hormone therapy
Final results from the RADICALS-HD clinical trial found no evidence that the addition of hormone therapy improved how long people lived without their cancer spreading, among patients whose doctors considered them suitable for short-term, long-term or no hormone therapy.
Spotlight on our research at ESMO Congress 2024
We will present our latest prostate cancer research from the PATCH, STAMPEDE and STAMPEDE2 trials at the 2024 ESMO Congress.
'25 at 25': Training and capacity strengthening
As part of our '25 at 25' series, we celebrate the Unit’s training and capacity strengthening efforts over the past two decades.
'25 at 25': OCTOPUS – speeding up new treatments for progressive MS
As part of our ’25 at 25’ series, we explore how the OCTOPUS trial in progressive multiple sclerosis (MS) aims to speed up the delivery of new treatments, bringing hope to the MS community.
'25 at 25': Conducting the first large international randomised controlled trial on tuberculosis treatment for children
As part of our ’25 at 25’ series, we look back at The SHINE trial, which was the first randomised controlled trial to assess the length of treatment needed for children with TB.